OncLive TV

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.

Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.

Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.

Myriam Chalabi, MD, highlights the importance of testing for microsatellite instability and mismatch repair deficiency in colorectal cancer.

Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses the impact of the coronavirus disease 2019 pandemic in renal cell carcinoma.

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.

Aman Chauhan, MD, discusses future directions with Lutathera in gastroenteropancreatic neuroendocrine tumors.

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.

Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

Elena Gabriela Chiorean, MD, discusses the role of genetic testing in pancreatic cancer.

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

Reema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.